Vision‐related quality of life in spondyloarthritis patients with history of acute anterior uveitis under treatment with golimumab: preliminary results of the GO‐VISION observational study

Abstract

AbstractPurposeAcute anterior uveitis (AAU) is one of the most common extra‐articular manifestations of spondyloarthritis (SpA), causing significant burden in quality of life (QoL). Golimumab (GLM) is a tumor necrosis factor‐inhibitor proven to be effective and safe in SpA. The GO‐EASY Study provided evidence that GLM decreases the AAU occurrence rate in SpA. Our aim is to study the impact of GLM in the change of vision‐related (VR) QoL in subjects with SpA and past or current AAU.MethodsOngoing prospective multicentre observational study (including 8 centres in Portugal) of SpA patients with history of AAU treated with GLM followed‐up for 12 months. We intend to recruit in total 30 patients and we report herein the 6 months outcomes for the first 9 patients enrolled. The occurrence of AAU was assessed in the 2 years before GLM treatment was started and the first 6 months of follow‐up and calculated for the period at risk for a new AAU. VR QoL was assessed with the self‐administered National Eye Institute Visual Functioning Questionnaire‐25 (NEI VFQ‐25). Adverse events were noted.ResultsNine patients (66.7% female, 100% TNFi‐naive, mean age 46.1 ± 14.4 years (range 22–65)) have completed 6 months of follow‐up. Three patients (33%) were also under oral methotrexate. The mean number of AAU flares in the 2 years preceding the start of GLM was 2.2 ± 1.3 (1–4). During the first 6 months of GLM treatment, the AAU incidence rate was reduced from 1.54 to 0.11 per 100 patient‐years (incidence ratio‐ratio 13.46, 95% CI 2.15–558.00; p < 0.01). At baseline and at 24 weeks after GLM onset, the mean overall index NEI VFQ‐25 total score was 70.2 and 83.2, respectively; improvement in the NEI VFQ‐25 total score was +13 ± 18.2. No significant or new adverse events occurred.ConclusionsPreliminary data from the GO‐VISION study suggest that GLM is safe and effective in patients with SpA and history of AAU, being able to reduce the AAU occurrence rate and potentially increasing VR QoL.